What is GestVision?
GestVision Inc. is dedicated to developing a diagnostic test for preeclampsia, a critical pregnancy complication marked by high blood pressure and proteinuria. The company aims to facilitate early detection and management of this condition, thereby preventing severe outcomes for expectant mothers and their infants. Their solution, the GestAssured Test, is designed for healthcare providers and individuals seeking enhanced prenatal care through advanced health monitoring.
How much funding has GestVision raised?
GestVision has raised a total of $7.2M across 2 funding rounds:
Angel/Seed
$100K
Private Equity
$7.1M
Angel/Seed (2014): $100K with participation from YEI Innovation Fund
Private Equity (2015): $7.1M, investors not publicly disclosed
Key Investors in GestVision
YEI Innovation Fund
The YEI Innovation Fund, a collaboration between Yale University, Connecticut Innovations, and First Niagara Bank, focuses on providing early-stage funding to promising ventures that have participated in Yale Entrepreneurial Institute programs. Their investment in GestVision suggests a focus on innovative health technology with strong academic ties.
What's next for GestVision?
The substantial enterprise-level funding positions GestVision for significant scaling and market penetration. This capital infusion is expected to accelerate the development and commercialization of the GestAssured Test, potentially revolutionizing prenatal care and reducing the incidence of severe preeclampsia-related complications. Future strategic investments will likely focus on expanding clinical validation, regulatory approvals, and global market reach.
See full GestVision company page
